These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 9178864)

  • 1. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
    Guyot MC; Hantraye P; Dolan R; Palfi S; Maziére M; Brouillet E
    Neuroscience; 1997 Jul; 79(1):45-56. PubMed ID: 9178864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum.
    Vis JC; Verbeek MM; De Waal RM; Ten Donkelaar HJ; Kremer HP
    Neuropathol Appl Neurobiol; 1999 Dec; 25(6):513-21. PubMed ID: 10632901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
    Ouary S; Bizat N; Altairac S; Ménétrat H; Mittoux V; Condé F; Hantraye P; Brouillet E
    Neuroscience; 2000; 97(3):521-30. PubMed ID: 10828534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.
    Beal MF; Brouillet E; Jenkins BG; Ferrante RJ; Kowall NW; Miller JM; Storey E; Srivastava R; Rosen BR; Hyman BT
    J Neurosci; 1993 Oct; 13(10):4181-92. PubMed ID: 7692009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
    Shear DA; Dong J; Gundy CD; Haik-Creguer KL; Dunbar GL
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1217-40. PubMed ID: 9829299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module.
    Garcia M; Vanhoutte P; Pages C; Besson MJ; Brouillet E; Caboche J
    J Neurosci; 2002 Mar; 22(6):2174-84. PubMed ID: 11896157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid.
    Nakao N; Brundin P
    Neuroscience; 1997 Feb; 76(3):749-61. PubMed ID: 9135048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms.
    Kumar P; Padi SS; Naidu PS; Kumar A
    Behav Pharmacol; 2006 Sep; 17(5-6):485-92. PubMed ID: 16940769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's Disease.
    Chakraborty J; Singh R; Dutta D; Naskar A; Rajamma U; Mohanakumar KP
    CNS Neurosci Ther; 2014 Jan; 20(1):10-9. PubMed ID: 24188794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease.
    Kodsi MH; Swerdlow NR
    Neurosci Lett; 1997 Aug; 231(2):103-7. PubMed ID: 9291151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease.
    Miller PJ; Zaborszky L
    Exp Neurol; 1997 Jul; 146(1):212-29. PubMed ID: 9225755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rutin against a mitochondrial toxin, 3-nitropropionicacid induced biochemical, behavioral and histological alterations-a pilot study on Huntington's disease model in rats.
    Suganya SN; Sumathi T
    Metab Brain Dis; 2017 Apr; 32(2):471-481. PubMed ID: 27928694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid.
    Araujo DM; Hilt DC
    Neuroscience; 1998 Jan; 82(1):117-27. PubMed ID: 9483508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
    Blum D; Gall D; Galas MC; d'Alcantara P; Bantubungi K; Schiffmann SN
    J Neurosci; 2002 Oct; 22(20):9122-33. PubMed ID: 12388620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease.
    Chakraborty J; Nthenge-Ngumbau DN; Rajamma U; Mohanakumar KP
    Behav Brain Res; 2014 May; 264():91-104. PubMed ID: 24509309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease.
    Sun Z; Xie J; Reiner A
    Exp Neurol; 2002 Jul; 176(1):55-65. PubMed ID: 12093082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats.
    Borlongan CV; Koutouzis TK; Randall TS; Freeman TB; Cahill DW; Sanberg PR
    Brain Res Bull; 1995; 36(6):549-56. PubMed ID: 7538873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic, but not intraparenchymal, administration of 3-nitropropionic acid mimics the neuropathology of Huntington's disease: a speculative explanation.
    Borlongan CV; Nishino H; Sanberg PR
    Neurosci Res; 1997 Jul; 28(3):185-9. PubMed ID: 9237266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid.
    El Massioui N; Ouary S; Chéruel F; Hantraye P; Brouillet E
    Exp Neurol; 2001 Nov; 172(1):172-81. PubMed ID: 11681849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease.
    Borlongan CV; Koutouzis TK; Freeman TB; Cahill DW; Sanberg PR
    Brain Res; 1995 Oct; 697(1-2):254-7. PubMed ID: 8593585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.